Quantum Leap Logo with a gradient

PARTNERSHIPS

Working together

The Efficient and Innovative design of I-SPY 2 offers all of our partners — clinical researchers, patient advocates, pharmaceutical and diagnostics companies, and non-profit charities — the opportunity to participate in and contribute to the acceleration of drug development to treat breast cancer patients in the neoadjuvant setting. 

A leap in collaboration begins here

The I-SPY Trials are always looking to discuss potential partnerships with companies interested in evaluating promising new agents or analytical methods.  To learn more about partnerships with I-SPY, please contact Paul Henderson at p.henderson@quantumleaphealth.org

OneSource AI

Leverage our database for deeper insights

OneSource AI provides access to secure analytic workspaces and data for partners to explore and develop models and AI algorithms leveraging data from the I-SPY family of trials.  Datasets include clinical, imaging, biomarker and sequencing data.

Learn more about OneSource.

For Investigators

Proposal Submissions

I-SPY 2 accepts proposals from investigators interested in accessing I-SPY data or clinical specimens for original research. The following information describes the general requirements, application and review processes. Interested applicants should familiarize themselves with this information prior to submission.

I-SPY 2 Leadership

Meet the leading minds leading our innovative cancer trials.

A leap in research happens with world-class partners.

Together with our incredible partners in the pharma and healthcare world,
we’re making bigger leaps than ever before to advance personalized medicine for all.

VIEW ALL PARTNERS

I-SPY Articles & Publications

Find the latest leaps happening near you.

I-SPY 2.2 is working. Why aren’t others replicating the design?

Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group

40-site U.S. trial enrolling more than 300 patients could significantly change the way DCIS is treated and reduce possibly unnecessary surgery

Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform (EOP) Clinical Trial

Quantum Leap Healthcare Collaborative™ today announced that Arvinas’ vepdegestrant (ARV-471), a novel PROTAC® estrogen receptor (ER) protein degrader being co-developed with Pfizer Inc. will be evaluated in the ongoing I-SPY TRIAL endocrine program sponsored by Quantum Leap.

Exai Bio and Quantum Leap Healthcare Collaborative Announce Expanded Participation in I-SPY 2 Trial to Advance Exai’s Novel RNA-based Liquid Biopsy Platform in Breast Cancer

Exai Bio today announced a collaboration agreement with Quantum Leap Healthcare Collaborative™ (QLHC) to expand the use of Exai’s novel, RNA-based liquid biopsy platform to monitor patients’ treatment response and disease burden in the I-SPY 2 TRIAL. I-SPY2 is the largest and longest-running 'platform' trial that provides a regulatory framework to study multiple novel therapeutic treatment arms for women with newly diagnosed, locally advanced breast cancer. 

ALL QLHC IN THE NEWS

Your financial support of any amount can
help make a huge leap in our efforts to
deliver personalized medicine for all.

Donate Here
© Quantum Leap Healthcare Collaborative. 2023-2024.

For Patients

For Investigators

Partnerships

About us

Trials
Resources
Contact Us

For Patients

For Investigators

Partnerships

About us

Studies
Collaborations
Publications
Contact Us
Donate
Investigators Portal

For Patients

For Investigators

Partnerships

About us

Partnerships
One Source
Donate

For Patients

For Investigators

Partnerships

About us

Our Approach
QLHC in the News
Working at QLHC
Contact Us
Donate